OverviewSuggest Edit

Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

TypePublic
Founded2002
HQPlano, TX, US
Websitereatapharma.com
Employee Ratings3.8
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)220(+79%)
Job Openings49
Revenue (FY, 2020)$9 M(-65%)
Share Price (Nov 2021)$102.5
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Reata Pharmaceuticals

Warren Huff

Warren Huff

Founding Chief Executive Officer and President, Director
Dawn C. Bir

Dawn C. Bir

Chief Commercial Officer and Executive Vice President
Colin Meyer

Colin Meyer

Chief Research & Development Officer and Executive Vice President
Manmeet S. Soni

Manmeet S. Soni

Chief Operating Officer & Chief Financial Officer and Executive Vice President
Elaine Castellanos

Elaine Castellanos

Chief Accounting Officer, Senior Vice President
Michael D. Wortley

Michael D. Wortley

Chief Legal Officer and Executive Vice President
Show more

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has offices in Plano and Irving
Plano, TX, US (HQ)
5320 Legacy Dr
Irving, TX, US
2801 Gateway Dr #150
Plano, TX, US
5340 Legacy Dr
Show all (3)

Reata Pharmaceuticals Financials and Metrics

Reata Pharmaceuticals Revenue

Reata Pharmaceuticals's revenue was reported to be $9.02 m in FY, 2020
USD

Revenue (FY, 2020)

9.0m

Net income (FY, 2020)

(247.8m)

Market capitalization (12-Nov-2021)

3.2b

Closing stock price (12-Nov-2021)

102.5

Cash (31-Dec-2020)

818.2m
Reata Pharmaceuticals's current market capitalization is $3.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

48.1m53.6m26.5m9.0m

Revenue growth, %

(4%)12%(51%)

General and administrative expense

23.3m32.7m58.3m75.1m

R&D expense

71.3m97.3m128.1m159.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

32.4m7.6m5.2m7.8m7.8m8.2m1.4m3.1m1.4m

General and administrative expense

6.6m10.7m7.5m10.0m11.7m14.3m20.8m16.6m18.3m

R&D expense

21.4m23.4m27.1m26.1m29.6m32.3m47.7m36.8m37.2m

Operating expense total

28.1m34.2m34.7m36.3m41.5m46.8m68.7m53.7m55.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

129.8m337.8m664.3m818.2m

Prepaid Expenses

3.3m4.5m5.0m7.0m

Current Assets

133.1m342.3m669.3m847.3m

PP&E

718.0k1.4m3.0m4.9m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(47.7m)(80.5m)(290.2m)(247.8m)

Depreciation and Amortization

437.0k431.0k932.0k1.1m

Accounts Payable

(1.8m)2.0m(2.1m)2.9m

Cash From Operating Activities

(83.3m)(83.8m)(251.2m)(322.3m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

4.1m(24.1m)(55.0m)(29.2m)(63.5m)(103.2m)(48.9m)(116.5m)(182.0m)

Depreciation and Amortization

101.0k206.0k311.0k170.0k401.0k659.0k278.0k562.0k851.0k

Accounts Payable

(1.1m)46.0k2.9m(522.0k)312.0k(440.0k)10.7m9.4m7.0m

Cash From Operating Activities

(24.0m)(49.4m)(46.3m)(28.7m)(61.4m)(101.8m)(41.2m)(237.1m)(277.2m)
USDFY, 2017

Revenue/Employee

516.8k

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.9 x
Show all financial metrics

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Patents Pending

280

Phase I Trials Products

2

Phase III Trials Products

1
Show all operating metrics

Reata Pharmaceuticals Revenue Breakdown

Embed Graph

Reata Pharmaceuticals revenue breakdown by business segment: 95.3% from License and Milestone and 4.7% from Other

Reata Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Reata Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Reata Pharmaceuticals Online and Social Media Presence

Embed Graph

Reata Pharmaceuticals Company Culture

  • Overall Culture

    B

    81/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Reata Pharmaceuticals News and Updates

Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME

Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences

PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1x1 meetings at the following investor conferences:

Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021

PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market …

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs

ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME

Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021

PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-m…

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of $140.85 …
Show more

Reata Pharmaceuticals Blogs

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020 Content Import Mon, 11/02/2020 - 17:30 Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Developmen…

Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

PLANO, Texas , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that results from the pivotal part 2 portion of the MOXIe trial evaluating the efficacy and safety of

Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors

PLANO, Texas , July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards , M.D. to its Board of Directors, effective August 3, 2020 .  Since 2003,

Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs

Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs Content Import Mon, 05/11/2020 - 16:02 Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs …

Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020

Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020 Content Import Mon, 05/04/2020 - 16:36 Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Developm…

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations Content Import Mon, 03/30/2020 - 16:06 Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations …
Show more

Reata Pharmaceuticals Frequently Asked Questions

  • When was Reata Pharmaceuticals founded?

    Reata Pharmaceuticals was founded in 2002.

  • Who are Reata Pharmaceuticals key executives?

    Reata Pharmaceuticals's key executives are Warren Huff, Dawn C. Bir and Colin Meyer.

  • How many employees does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 220 employees.

  • What is Reata Pharmaceuticals revenue?

    Latest Reata Pharmaceuticals annual revenue is $9 m.

  • What is Reata Pharmaceuticals revenue per employee?

    Latest Reata Pharmaceuticals revenue per employee is $41 k.

  • Who are Reata Pharmaceuticals competitors?

    Competitors of Reata Pharmaceuticals include Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Apellis Pharmaceuticals.

  • Where is Reata Pharmaceuticals headquarters?

    Reata Pharmaceuticals headquarters is located at 5320 Legacy Dr, Plano.

  • Where are Reata Pharmaceuticals offices?

    Reata Pharmaceuticals has offices in Plano and Irving.

  • How many offices does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 3 offices.